Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-18
DOI
10.3389/fneur.2021.700007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas—A German Survey
- (2020) Ulf Elbelt et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary-Tumor Endocrinopathies
- (2020) Shlomo Melmed NEW ENGLAND JOURNAL OF MEDICINE
- Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature
- (2020) Laura Lizzul et al. Pituitary
- Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas
- (2020) Giuseppe Minniti et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor
- (2020) Tae Nakano-Tateno et al. ENDOCRINE PATHOLOGY
- Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma: a new emerging treatment?
- (2020) Bastiaan Sol et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review
- (2019) Yong Wang et al. World Neurosurgery
- Surgery, octreotide, temozolomide, bevacizumab, radiotherapy and pegvisomant treatment of an AIP mutation positive child
- (2019) Pinaki Dutta et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment and long-term outcomes in pituitary carcinoma: a cohort study
- (2019) Fernando Santos-Pinheiro et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications
- (2019) George Kontogeorgos et al. Pituitary
- Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities
- (2019) George Kontogeorgos et al. Hormones-International Journal of Endocrinology and Metabolism
- Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide
- (2018) Erica H. Bell et al. JAMA Oncology
- A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
- (2018) Xiaoyue Chen et al. Nature Communications
- Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
- (2017) Hélène Lasolle et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification
- (2017) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Course of aggressive somatotroph, corticotroph and mammotroph tumors under temozolomide; report of three cases and review of the literature
- (2017) Berna Imge Aydogan et al. Turkish Neurosurgery
- Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma
- (2017) Ismene Bilbao et al. Endocrinologia Diabetes y Nutricion
- Management of hormone-secreting pituitary adenomas
- (2016) Gautam U. Mehta et al. NEURO-ONCOLOGY
- Expression profiling of O6 methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases
- (2015) Xiao-Bing Jiang et al. BMC CANCER
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center
- (2015) Filippo Ceccato et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
- (2015) Marco Losa et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
- (2015) Oscar D. Bruno et al. International Journal of Endocrinology
- Aggressive pituitary adenomas—diagnosis and emerging treatments
- (2014) Antonio Di Ieva et al. Nature Reviews Endocrinology
- Implications of MGMT methylation status in pituitary adenoma
- (2014) Sneha Arya et al. PATHOLOGY RESEARCH AND PRACTICE
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- Inhibition of PI3K/AKT/mTOR Pathway Enhances Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro and Xenografted Pituitary Adenoma in Female Nude Mice
- (2013) Congxin Dai et al. ENDOCRINOLOGY
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Changes in pituitary function with ageing and implications for patient care
- (2013) Johannes D. Veldhuis Nature Reviews Endocrinology
- High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)
- (2013) Brad E. Zacharia et al. NEUROSURGERY
- Temozolomide in the management of dopamine agonist-resistant prolactinomas
- (2012) B. C. Whitelaw et al. CLINICAL ENDOCRINOLOGY
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment
- (2012) Gérald Raverot et al. CLINICAL ENDOCRINOLOGY
- Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases
- (2010) Marco Losa et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
- (2009) C Hagen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS
- (2009) Safraz Mohammed et al. NEUROSURGERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started